AC Immune (ACIU)
(Delayed Data from NSDQ)
$3.63 USD
+0.17 (4.91%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $3.63 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.63 USD
+0.17 (4.91%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $3.63 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Zacks News
Biogen Inks Two Deals to Make Drugs for Neurological Diseases
by Zacks Equity Research
Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.
Lilly Inks Deal With AC Immune for Potential Alzheimer's Drug
by Zacks Equity Research
Eli Lilly (LLY) signs a deal with AC Immune to jointly develop Morphomer tau aggregation inhibitors, which have the potential to treat Alzheimer's disease (AD) and other neurodegenerative diseases.
AC Immune (ACIU) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in AC Immune SA (ACIU).
Top Ranked Momentum Stocks to Buy for November 21st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 21st:
AC Immune (ACIU) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 30.77% and 36.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline
by Zacks Equity Research
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune (ACIU) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 13.04% and 5.78%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Puma Biotech (PBYI) in Q2 Earnings?
by Zacks Equity Research
On Puma Biotechnology's (PBYI) second-quarter 2018 earnings call, investor focus will be on the sales figures of its only marketed drug Nerlynx.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
During Inovio's (INO) second-quarter 2018 earnings call, investor focus will remain on the company's progress with its lead candidate VGX-3100.
Moving Average Crossover Alert: AC Immune SA (ACIU)
by Zacks Equity Research
AC Immune SA (ACIU) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Fortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session
by Zacks Equity Research
Fortress Biotech, Inc. (FBIO) shares rose over 5% in the last trading session.